{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:03:07Z","timestamp":1792094587026,"version":"4.4.0"},"reference-count":82,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.4103\/idoj.idoj_542_22","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T03:35:05Z","timestamp":1678419305000},"page":"153","source":"Crossref","is-referenced-by-count":12,"title":["Emerging role of baricitinib in dermatology practice: All we need to know!"],"prefix":"10.4103","volume":"14","author":[{"given":"Sunil","family":"Dogra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikha","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.371524-1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","article-title":"Baricitinib: First global approval","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"key-10.4103\/2229-5178.371524-2","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of janus kinase inhibitor selectivity","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"key-10.4103\/2229-5178.371524-3","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.2147\/JIR.S356316","article-title":"Application of baricitinib in dermatology","author":"Zhang","year":"2022","journal-title":"J Inflamm Res"},{"key":"key-10.4103\/2229-5178.371524-4","unstructured":"Petrou I. Alopecia areata gets FDA-approved drug. Dermatol Times 2022;43."},{"key":"key-10.4103\/2229-5178.371524-5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1039\/C8MD90019A","article-title":"What are the drugs of the future?","author":"Ngo","year":"2018","journal-title":"Med Chem Comm"},{"key":"key-10.4103\/2229-5178.371524-6","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1002\/jcph.354","article-title":"The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1\/2 inhibitor, in healthy volunteers","author":"Shi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"key-10.4103\/2229-5178.371524-7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3390\/ph14100955","article-title":"Pharmacology and adverse events of emergency-use authorized medication in moderate to severe COVID-19","author":"Hsu","year":"2021","journal-title":"Pharmaceuticals"},{"key":"key-10.4103\/2229-5178.371524-8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","author":"Thomas","year":"2015","journal-title":"Br J Cancer"},{"key":"key-10.4103\/2229-5178.371524-9","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/2229-5178.371524-10","first-page":"311\u2013328","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention.Annu Rev Med","author":"O'Shea","year":"2015","journal-title":""},{"key":"key-10.4103\/2229-5178.371524-11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.371524-12","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/jm801142b","article-title":"Examining the chirality, conformation and selective kinase inhibition of 3-((3 R, 4 R)-4-methyl-3-(methyl (7H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino) piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)","author":"Jiang","year":"2008","journal-title":"J Med Chem"},{"key":"key-10.4103\/2229-5178.371524-13","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.molimm.2006.11.025","article-title":"Cytokine receptor signaling through the Jak\u2013Stat\u2013Socs pathway in disease","author":"O'Sullivan","year":"2007","journal-title":"Mol Immunol"},{"key":"key-10.4103\/2229-5178.371524-14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"key-10.4103\/2229-5178.371524-15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: The second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","author":"Mogul","year":"2019","journal-title":"Ann Pharmacother"},{"key":"key-10.4103\/2229-5178.371524-16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.drudis.2020.11.025","article-title":"Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic","author":"Rizk","year":"2021","journal-title":"Drug Discov Today"},{"key":"key-10.4103\/2229-5178.371524-17","first-page":"104157","article-title":"Olumniant (Baricitinib) oral tablets: An insight into FDA-approved systemic treatment for Alopecia Areata","author":"Ali","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"key-10.4103\/2229-5178.371524-18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.371524-19","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/09546634.2022.2116926","article-title":"JAK inhibitors in lichen planus: A review of pathogenesis and treatments","author":"Motamed-Sanaye","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/2229-5178.371524-20","first-page":"e15728","article-title":"Baricitinib rapidly relieves eczema associated pruritus in elderly patients","author":"Hong","year":"2022","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.371524-21","first-page":"e15724","article-title":"Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus kinase inhibitor baricitinib","author":"Xia","year":"2022","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.371524-22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1586\/17512433.2016.1145543","article-title":"Upcoming therapeutic targets in cutaneous lupus erythematous","author":"Klaeschen","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"key-10.4103\/2229-5178.371524-23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jaad.2022.08.025","article-title":"Baricitinib for the treatment of cutaneous dermatomyositis: A prospective, open-label study","author":"Zhao","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.371524-24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdcr.2022.07.013","article-title":"Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate","author":"Burningham","year":"2022","journal-title":"JAAD Case Rep"},{"key":"key-10.4103\/2229-5178.371524-25","first-page":"e15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.371524-26","doi-asserted-by":"crossref","first-page":"859330","DOI":"10.3389\/fmed.2022.859330","article-title":"JAK1\/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis","author":"Hou","year":"2022","journal-title":"Front Med"},{"key":"key-10.4103\/2229-5178.371524-27","first-page":"e15712","article-title":"Successfully treated extragenital lichen sclerosus in a 2-year-old boy by baricitinib assessed by dermoscopy: A case report","author":"Su","year":"2022","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.371524-28","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","author":"Choi","year":"2018","journal-title":"Leukemia"},{"key":"key-10.4103\/2229-5178.371524-29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1001\/jamadermatol.2022.1021","article-title":"Response of darier disease following treatment with baricitinib","author":"Leis","year":"2022","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.371524-30","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1001\/jamadermatol.2021.3174","article-title":"Epidermolysis bullosa pruriginosa treated with baricitinib","author":"Jiang","year":"2021","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.371524-31","doi-asserted-by":"crossref","first-page":"7474","DOI":"10.3390\/ijms22147474","article-title":"Baricitinib, a JAK-STAT inhibitor, reduces the cellular toxicity of the farnesyltransferase inhibitor lonafarnib in progeria cells","author":"Arnold","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key-10.4103\/2229-5178.371524-32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s13555-021-00517-9","article-title":"Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: A scoping review","author":"G\u00f3mez-Arias","year":"2021","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.371524-33","first-page":"15593258221105370","article-title":"Baricitinib is effective in treating progressing vitiligo in vivo and in vitro.Dose-Response","author":"Dong","year":"2022","journal-title":""},{"key":"key-10.4103\/2229-5178.371524-34","first-page":"e15659","article-title":"Refractory livedoid vasculopathy in a child successfully treated with baricitinib","author":"Zhang","year":"2022","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.371524-35","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/ced.14712","article-title":"Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated sweet syndrome","author":"Nousari","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/2229-5178.371524-36","first-page":"e500","article-title":"Successful treatment of generalized granuloma annulare with baricitinib","author":"Yan","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.371524-37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/ajd.13786","article-title":"Successful treatment of folliculitis decalvans with baricitinib: A case series","author":"Moussa","year":"2022","journal-title":"Australas J Dermatol"},{"key":"key-10.4103\/2229-5178.371524-38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/ced.15044","article-title":"Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia","author":"Kreuter","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/2229-5178.371524-39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/jamadermatol.2021.5579","article-title":"Treatment of progressive nodular histiocytosis with baricitinib","author":"Huang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.371524-40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/bjd.16808","article-title":"Alopecia areata: A review of disease pathogenesis","author":"Rajabi","year":"2018","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.371524-41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.371524-42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.371524-43","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-5178.371524-44","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/CCID.S309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","author":"Dillon","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"key-10.4103\/2229-5178.371524-45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"key-10.4103\/2229-5178.371524-46","first-page":"e472","article-title":"Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report","author":"Uchida","year":"2021","journal-title":"J Dermatol"},{"key":"key-10.4103\/2229-5178.371524-47","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.15937","article-title":"Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta-analysis","author":"Guo","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.371524-48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s41687-020-00240-7","article-title":"\u201c'You lose your hair, what's the big deal.' I was so embarrassed, I was so self-conscious, I was so depressed:\u201d A qualitative interview study to understand the psychosocial burden of alopecia areata?","author":"Aldhouse","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"key-10.4103\/2229-5178.371524-49","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/healthcare9111575","article-title":"Baricitinib: The first jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients","author":"Radi","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"key-10.4103\/2229-5178.371524-50","unstructured":"UK national institute for health excellence. Baricitinib for treating moderate to severe atopic dermatitis: Technology appraisal guidance (TA681). 2021. https:\/\/www.nice.org.uk\/guidance\/ta681. Accessed September 15, 2022."},{"key":"key-10.4103\/2229-5178.371524-51","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40257-022-00684-1","article-title":"Baricitinib: A review in moderate to severe atopic dermatitis","author":"Hoy","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/2229-5178.371524-52","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: An extension study of 2 randomized clinical trials","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.371524-53","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: A review","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol Ther"},{"key":"key-10.4103\/2229-5178.371524-54","first-page":"e391","article-title":"Baricitinib-induced paradoxical psoriasis","author":"Di","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.371524-55","unstructured":"Ahmad A, Zaheer M, Balis FJ. Baricitinib. 2022 Jul 27. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan\u2013. PMID: 34283430."},{"key":"key-10.4103\/2229-5178.371524-56","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14740338.2020.1743263","article-title":"The safety of baricitinib in patients with rheumatoid arthritis","author":"Honda","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"key-10.4103\/2229-5178.371524-57","doi-asserted-by":"crossref","first-page":"1759720X19899296","DOI":"10.1177\/1759720X19899296","article-title":"Baricitinib exposure during pregnancy in rheumatoid arthritis","author":"Costanzo","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"key-10.4103\/2229-5178.371524-58","unstructured":"Baricitinib O. EU summary of product characteristics: Olumiant. Utrecht, Netherlands: Eli Lilly Nederland BV [Google Scholar]. 2018."},{"key":"key-10.4103\/2229-5178.371524-59","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaad.2021.04.077","article-title":"Treatment of pediatric alopecia areata: A systematic review","author":"Barton","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.371524-60","unstructured":"A Study of Baricitinib (LY3009104) in Children and Adolescents with Atopic Dermatitis (BREEZE-AD-PEDS) [(accessed on 2 November 2021)]; Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03952559."},{"key":"key-10.4103\/2229-5178.371524-61","unstructured":"Olumiant (Baricitinib) [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207924s006lbl.pdf. Accessed September 11, 2022"},{"key":"key-10.4103\/2229-5178.371524-62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/2229-5178.371524-63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.31138\/mjr.31.1.129","article-title":"Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies","author":"Thomas","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"key-10.4103\/2229-5178.371524-64","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.16948","article-title":"Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials","author":"Bieber","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.371524-65","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","article-title":"A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19","author":"Bieber","year":"2022","journal-title":"Adv Ther"},{"key":"key-10.4103\/2229-5178.371524-66","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"key":"key-10.4103\/2229-5178.371524-67","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"key-10.4103\/2229-5178.371524-68","first-page":"Final results from long","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9","author":"Taylor","year":"3 ye","journal-title":""},{"key":"key-10.4103\/2229-5178.371524-69","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","author":"Diamond","year":"2011","journal-title":"J Exp Med"},{"key":"key-10.4103\/2229-5178.371524-70","first-page":"7390","article-title":"\u201cClinical aspects of Janus Kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis","author":"Kotyla","year":"8221","journal-title":"arthritis"},{"key":"key-10.4103\/2229-5178.371524-71","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"key-10.4103\/2229-5178.371524-72","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"key-10.4103\/2229-5178.371524-73","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","article-title":"Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: A systematic review and meta-analysis","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"key":"key-10.4103\/2229-5178.371524-74","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40257-022-00701-3","article-title":"JAK in the [black] box: A dermatology perspective on systemic JAK inhibitor safety","author":"Elmariah","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/2229-5178.371524-75","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus kinase inhibitor selectivity","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"key-10.4103\/2229-5178.371524-76","doi-asserted-by":"crossref","first-page":"AB176","DOI":"10.1016\/j.jaad.2022.06.737","article-title":"33966 Integrated safety analysis of baricitinib in adults with severe alopecia areata from 2 randomized clinical trials","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.371524-77","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"key-10.4103\/2229-5178.371524-78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"key-10.4103\/2229-5178.371524-79","first-page":"1046","article-title":"Characteristics of adverse event reporting of Xeljanz\/Xeljanz XR, olumiant, and rinvoq to the US food and drug administration","author":"Qian","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"key-10.4103\/2229-5178.371524-80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaad.2021.09.051","article-title":"Special editorial: When prescribing janus kinase inhibitors for dermatologic conditions, be mindful of the food and drug administration's September 1, 2021, data safety communication","author":"Murphrey","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.371524-81","doi-asserted-by":"crossref","first-page":"950450","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies","author":"Yan","year":"2022","journal-title":"Front Pharmacol"},{"key":"key-10.4103\/2229-5178.371524-82","first-page":"e15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis","author":"Wan","year":"2022","journal-title":"Dermatol Ther"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:10:54Z","timestamp":1787065854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_542_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"alternative-id":["371524"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_542_22","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}